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 Abstract 
 SPRASA (also referred to as SLLP1) is a protein identifi ed in the acrosome of human sperm and encoded by the gene  SPACA3 . 
SPRASA is associated with sperm-oocyte recognition and binding, and may play a role in fertility. In order to determine whether 
variants in the  SPACA3 gene are associated with human infertility, we undertook a genetic analysis of 102 infertile and 104 fertile 
couples. Three gene variants were identifi ed using PCR-based DNA sequencing; 1) an insertion of TGC within a quadruple tri-
nucleotide (TGC) repeat region in the 5 ′ untranslated region (UTR) (g. – 22TGC(4_5), 2) a guanine to adenosine transition at 
position 239 (c.239G  A) resulting in a non-synonymous amino acid substitution from cysteine to tyrosine (p.C80Y) at position 
80 in the putative transmembrane region, and 3) a novel nucleotide variant (c.691G   C) located in the 3 ′ UTR. A functional effect 
of the g. – 22TGC (4_5) was confi rmed by a luciferase expression assay, while the effects of the variants c.239G  A and c.691G   C 
were predicted using  in silico analysis. Although the frequencies of these variants were not signifi cantly different between the infer-
tile and fertile populations, we present evidence that the variants could affect the expression levels or function of SPRASA , thereby 
affecting a couple ’ s fertility. Larger populations, especially individuals/couples with unexplained infertility, need to be screened for 
these variants to validate a relationship with fertility. 
 Keywords:  Reproduction ,  gene mutation ,  unexplained infertility 
 Introduction 
 The prevalence of infertility in Western countries such 
as New Zealand is estimated to be one in six couples, 
while one in eight couples require some form of medi-
cal assistance to achieve a pregnancy (HFEA, 2006). 
Of these infertile cases, the precise cause of infertility 
for approximately 5 – 15% of couples is unknown, and is 
referred to as unexplained infertility (Farquhar, 1998; 
Liu et  al., 2007). Standard investigations, including 
testing for ovulation, tubal patency and semen analysis 
are routine in these couples (Kamath  & Bhattacharya, 
2012). The causes of unexplained infertility and infertil-
ity, in general, are likely to be heterogeneous, and may 
include endocrine, immunological, and genetic factors 
(Kamath  & Bhattacharya, 2012; Pellicer et  al., 1998). 
It is also common to fi nd multiple potential causes of 
infertility in an infertile couple (Collins  & Crosignani, 
1992; Marrero  & Ory, 1991; Quaas  & Dokras, 2008). 
 SPRASA (also referred to as SLLP1) is a protein 
identifi ed in the acrosome of human sperm (Chi et  al., 
2004). SPRASA is a member of the c-type lysozyme/
alpha-lactalbumin family (Chiu et  al., 2004; Mandal 
et  al., 2003), and human SPRASA is encoded by a gene 
( SPACA3 ) at chromosomal locus 17q11.2 (Mandal 
et  al., 2003). SPRASA is known to be the target for anti-
sperm antibodies in some infertile men, and this protein 
has been shown to have roles in sperm – oocyte binding 
and early embryo development in murine, hamster, or 
bovine models (Chiu et  al., 2004; Mandal et  al., 2003; 
Zhang et  al., 2005; A. Wagner, unpublished). SPRASA 
expression was thought to be limited to the sperm/
testis and some tumour cells, but we have recently dem-
onstrated it is also expressed by oocytes (A. Wagner, 
unpublished). This pattern of gonad/gamete-specifi c 
expression also supports the concept that SPRASA 
has an important role in fertility (Herrero et  al., 2005; 
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Mandal et  al., 2003; Wagner, 2009). While we discov-
ered SPRASA as the antigen for antisperm antibodies 
in some infertile men, the association of SPRASA with 
human infertility has not been investigated further. 
Because of SPRASA ’ s putative importance in fertility, 
naturally occurring genetic variation that disrupts the 
function of SPRASA may have a role in human infer-
tility. This study was undertaken to investigate whether 
genetic variants in the SPRASA-encoding  SPACA3 gene 
are associated with infertility in humans. 
 Methods and materials 
 Ethics statement and study population 
 This study was approved by the Northern Regional 
Ethics Committee (Auckland, New Zealand). Blood 
samples obtained by venipuncture were collected 
following written informed consent from 102 infer-
tile couples, (recruited through Fertility Associates, 
Auckland and Fertility Plus, Auckland; Supplemen-
tary Table I available online at: http//informahealth-
care.com/doi/abs/10.3109/14647273.2014.907506) 
and 104 fertile couples (recruited from the general 
Auckland population through media advertisement; 
Supplementary Table II available online at: http//
informahealthcare.com/doi/abs/10.3109/14647273
.2014.907506). Couples were defi ned as infertile if 
they were unable to conceive after one year of regu-
lar intercourse without the use of contraception. The 
clinically diagnosed disorders affecting the infertile 
cohort recruited for this study are summarised in 
Supplementary Table I available online at: http//infor-
mahealthcare.com/doi/abs/10.3109/14647273.2014.
907506. Couples were defi ned as fertile if they had 
given birth in the previous 2 years. 
 Mutation nomenclature 
 In accordance with current mutation nomenclature 
(den Dunnen  & Antonarakis, 2001), the adenosine of 
the ATG (initiator methionine codon) of  SPACA3 is 
denoted nucleotide    1. Nucleotide numbers refer to 
GenBank accession number NM_173847. 
 Polymerase chain reaction 
 Genomic DNA was extracted from 5 to 10 mL of blood 
using the salting out protocol (Miller et  al., 1988). Eight 
sets of Polymerase chain reaction (PCR) primers were 
designed to fl ank exons and the putative promoter re-
gions of  SPACA3 (Supplementary Table III available 
online at: http//informahealthcare.com/doi/abs/10.31
09/14647273.2014.907506). Genomic DNA (100ng) 
was amplifi ed using standard PCR conditions (Supple-
mentary Tables III and IV available online at: http//
informahealthcare.com/doi/abs/10.3109/14647273.2014.
907506). All PCR amplifi cations were performed in an 
iCycler (BioRad, Hempstead, UK). The PCR products 
were analysed using agarose gel electrophoresis, stained 
with ethidium bromide (10mg/ml; Sigma, Australia) 
and visualised under UV light. 
 DNA sequencing 
 The PCR products were purifi ed with the Roche High 
Pure PCR Product Purifi cation Kit (Roche, Basel, 
Switzerland) following the manufacturer ’ s instructions. 
Sequencing reactions were performed using the ABI 
prism Big Dye Terminator Sequencing Kit v3.1 (ABI, 
Foster City, USA) following the manufacturer ’ s instruc-
tions in a 20  μ L volume with approximately 5 ng per 
100 bp of PCR product. All primers used in the sequenc-
ing reactions allowed for 100% coverage of the coding 
region for each sample. Sequencing reactions for exon 
four were supplemented with betaine at a fi nal con-
centration of 1.4M to assist sequencing through 
secondary structures (Haqqi et  al., 2002). The vari-
ants were confi rmed by sequence replication. Se-
quencing of the promoter variants was carried out in 
both directions using internal primers (Supplemen-
tary Table III available online at: http//informahealth-
care.com/doi/abs/10.3109/14647273.2014.907506)
. Sequencing was amplifi ed using standard conditions 
(Supplementary Table VI available online at: http//
informahealthcare.com/doi/abs/10.3109/14647273.
2014.907506). Sequencing extension products were pre-
cipitated by MgSO 4 . Capillary electrophoresis was analy-
sed on a 3100 Genetic Analyser (Applied Biosystems, 
Life Technologies New Zealand Limited, Auckland) at 
the Genome Research Facility at the School of Biological 
Sciences, The University of Auckland. 
 Luciferase assay for promoter function: variant 
g. – 22TGC(4_5) 
 The three putative promoters isolated in this study, Pro-
moter A (located fi ve-prime of exon one; major allele; 
983bp), Promoter A g. – 22TGC(4_5) variant (located 
fi ve-prime of exon one; 986bp) and Promoter B (located 
in intron one; invariant; Figure 1), were investigated for 
their capacity to support transcriptional activity using 
luciferase assay. 
 Promoter A, Promoter A g. – 22TGC(4_5) variant 
and Promoter B were cloned upstream of the fi refl y 
luciferase gene of the pGL3-enhancer reporter plasmid 
(Promega, Wisconsin, USA). The cell lines HEK-293T 
(non- SPACA3 expressing negative control; human 
embryonic kidney; American Type Culture Collection, 
Manassas, USA), NCCIT ( SPACA3 expressing terato-
carcinoma; human pluripotent embryonal carcinoma; 
American Type Culture Collection, Manassas, USA) 
and KGN ( SPACA3 expressing granulosa; human 
granulosa cell tumour originated from a stage III granu-
losa cell tumour of the ovary; provided by Dr Ashwini 
Chand, Prince Henry ’ s Institute of Medical Research, 
Victoria, Australia) were co-transfected with the RL-
Tk vector (Promega, In vitro Technologies, Auckland) 
and either the (1) pGL3-Promoter A construct, (2) 
pGL3-Promoter A g. – 22TGC(4_5) variant construct, 
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(3) Promoter B construct or (4) pGL3 empty vec-
tor. Cells were transfected using Lipofectamine 2000 
(Invitrogen, Auckland) according to the manufacturer ’ s 
instructions. Cells were cultured for 24 h in RPMI 1640 
medium (Invitrogen, Auckland) supplemented with 
2mM L-glutamine (Invitrogen, Auckland) and 10% 
fetal calf serum (Invitrogen, Auckland). All cell lines 
were maintained at 37 ° C in 5% CO 2 . 
 Luciferase assays were performed using the Dual 
Luciferase Reporter Assay System (Promega, In vitro 
Technologies, Auckland) following the manufacturer ’ s 
instructions. The promoter assays were normalised to 
Renilla luciferase activity from the co-transfected pRL-
Tk vector. The means and standard error (SE) were 
calculated from identical transfections in triplicate from 
three independent experiments, and the two  SPACA3 
promoter variants were compared to the empty control 
plasmid transfected into the appropriate cell lines. 
 In silico analysis for function: variants g.  – 22TGC(4_5), 
c.239G  A and c.691G   C 
 The putative effects of the sequence variations on 
genetic association were predicted using the SHEsis 
programme (Shi  & He, 2005). The TESS (transcrip-
tion element search software) prediction tool was used 
to determine whether the g. – 22TGC(4_5) variant 
affected transcription factor binding (Schug  & Overton, 
1997). The possible impact of the amino acid substitu-
tion p.C80Y (genetic variant c.239G  A) on the struc-
ture, function and expression of the SPRASA protein 
was tested using the three prediction tools; SIFT (sorts 
intolerant from tolerant) scores were classifi ed as intol-
erant (0.00 – 0.05), potentially intolerant (0.051 – 0.10), 
borderline (0.101 – 0.20) or tolerant (0.201 – 1.00) 
(Ng  & Henikoff, 2003; Xi et  al., 2004); PolyPhen II 
(polymorphism phenotyping), scores were designated 
probably damaging (   2.00), possibly damaging (1.50 –
 1.99), potentially damaging (1.25 – 1.49), borderline 
(1.00 – 1.24) or benign (0.00 – 0.99) (Xi et  al., 2004); 
Grantham matrix scores categorise codon replacement 
into classes of increasing chemical dissimilarity and are 
designated conservative (0 – 50), moderately conserva-
tive (51 – 100), moderately radical (101 – 150) or radical 
(   151) (Grantham, 1974; Li et  al., 1984; Rudd et  al., 
2005). The potential effect on microRNA (miRNA) 
binding to the variant c.691G   C was analysed 
using the TargetScanHuman version 6.2 programme. 
TargetScan predicts biological targets of miRNAs by 
searching for the presence of conserved 8mer and 7mer 
sites that match the seed region of each miRNA (Lewis 
et  al., 2005), also identifi ed are sites with mismatches 
in the seed region that are compensated by conserved 
3 ′ pairing (Friedman et  al., 2009). In mammals, pre-
dictions are ranked based on the predicted effi cacy of 
targeting as calculated using the context scores of the 
sites (Grimson et  al., 2007). 
 Sequence alignments 
 In order to obtain a measure of the level of evolutionary 
conservation of the variants, multiple sequence align-
ments of  SPACA3 were performed as relevant for each 
variant using known orthologs with complete sequences 
in the programme Clustal W2. Thirteen higher primates 
possess known orthologs to human exon one contain-
ing the g. – 22TGC(4_5) variant, 42 mammalian species 
possess known orthologs to human exon two containing 
the c.239G  A variant, and 23 mammalian species pos-
sess known orthologs to human exon fi ve containing the 
c.691G   C variant. 
 Statistical analysis 
 The chi-squared statistic was used to detect the Hardy-
Weinberg equilibrium (HWE) for the three identifi ed 
sequence variations. The odds ratios and 95% con-
fi dence interval were used to measure the association 
in the genotype and allele distribution of the three 
sequence variations between the infertile and fertile 
groups. The p values were estimated using chi-square 
test. Statistical analysis from the results of the luciferase 
assay comparing the promoter variants was determined 
using unpaired Student ’ s T-test in the Graph Pad Prism 
 Figure 1. The genomic organisation of human  SPACA3 and the 
location of variants identifi ed in this study. (A) Schematic diagram 
of  SPACA3 ; exons are shown in  dark grey , introns are shown in  light 
grey and the putative promoters (A and B) are indicated by  grey 
arrows . The location of the variants g. – 22TGC(4_5), c.239G  A and 
c.691G   C are indicated by  black triangles on magnifi ed sections. (B) 
Representative electropherograms of the variants g. – 22TGC(4_5), 
c.239G  A and c.691G   C. 
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5.02 programme. All p values were two-tailed and con-
sidered signifi cant if  p    0.05. 
 Results 
 In order to investigate the population level variation in 
 SPACA3 and to determine whether this variation is as-
sociated with infertility, 102 infertile couples ( n    204 
individuals) and 104 fertile couples ( n    208 individu-
als) were analysed. Three sequence variants were iden-
tifi ed in this population; g. – 22TGC(4_5), c.239G  A 
and c.691G   C (Figure 1; Table I). 
 SPACA3 is well conserved in the cohort investigat-
ed; the minor allele frequencies for the variants were 
g. – 22TGC(4_5) 0.12, c.239G  A 0.02 and c.691G   C 
0.001. The variant c.691G   C was found at a popula-
tion frequency of less than 0.01, and is thus defi ned as 
a mutation (den Dunnen  & Antonarakis, 2001). There 
were a number of couples from the infertile and fertile 
cohorts who had a combination of multiple variants 
(Supplementary Table VII available online at: http//
informahealthcare.com/doi/abs/10.3109/14647273.
2014.907506). The variants identifi ed consisted of one 
in-frame insertion and two single nucleotide polymor-
phisms (details below). 
 SPACA3 /SPRASA is highly evolutionarily conserved. 
A multiple sequence alignment of  SPACA3 orthologs 
showed 100% conservation of the major variant in exons 
one and fi ve (Figure 2). Analysis of  SPACA3 orthologs 
in mammals showed that the guanosine/cytosine is con-
served (100% conservation in 42 species; Figure 2). 
 The fi rst variant in the  SPACA3 gene consists of the 
insertion of an additional TGC within a quadruple tri-
nucleotide TGC repeat region, g. – 22TGC(4_5), and is 
situated in the 5 ’ UTR of exon one (Figure 1). Allele 
frequencies for infertile and fertile individuals are shown 
in Table II. Diagnoses of infertile individuals with this 
variant are shown in Supplementary Table VIII available 
online at: http//informahealthcare.com/doi/abs/10.3109/
14647273.2014.907506. The frequencies of this variant 
in the infertile and fertile individuals were calculated to 
be in HWE and were not signifi cantly different between 
the infertile and fertile individuals ( p    0.24). 
 In order to investigate the potential consequences 
of this  SPACA3 variant on promoter function, we con-
ducted luciferase reporter experiments using three cell 
lines.  In vitro luciferase reporter assays comparing Pro-
moter A (located fi ve-prime of exon one; major allele) 
and Promoter A g. – 22TGC(4_5) variant (located fi ve-
prime of exon one) found expression from Promoter 
A in the  SPACA3 -expressing granulosa cell line KGN, 
with an approximately 1.4-fold increase in expression 
compared to the control. There was no expression 
above the normalisation-control from Promoter A in 
the  SPACA3 -expressing seminoma cell line NCCIT or 
the non- SPACA3 -expressing embryonic kidney cell line 
HEK-293T. Promoter A g. – 22TGC(4_5) variant did 
not induce expression above the normalisation-control 
in any cell line; there was a signifi cant difference be-
tween Promoter A and Promoter A g. – 22TGC(4_5) 
variant expression in the reproductively relevant KGN 
cell line ( p    0.01; Figure 3). The function of Promoter 
B (located in intron one; invariant) was also assessed. 
Expression from Promoter B was found in the NNCIT 
(approximately 2.7-fold increase compared to the con-
trol) and KGN (approximately 5.6-fold increase com-
pared to the control) cell lines. There was no expression 
above the normalisation-control from Promoter B in the 
HEK-293T cell line (Figure 3). 
 The second variant, a guanosine to adenosine tran-
sition at position 239, c.239G   A, was identifi ed in 
exon two, which encodes the putative transmembrane 
region of the SPRASA protein (Figure 1). This tran-
sition occurred at the second residue of the codon 
and resulted in a non-synonymous amino acid sub-
stitution at codon position 80 from a cysteine to a 
tyrosine (p.C80Y). Allele frequencies for infertile and 
fertile individuals are shown in Table II. Diagnoses of 
infertile individuals with this variant are shown in 
Supplementary Table VIII available online at: http//
informahealthcare.com/doi/abs/10.3109/14647273.
2014.907506. The frequencies of this variant in the 
infertile and fertile individuals were calculated to be in 
HWE and were not signifi cantly different between the 
infertile and fertile individuals ( p    0.36). 
 To determine possible effects that the c.239G  A 
variant may have on the function of the transmembrane 
region, online prediction tools were used to examine the 
effect of the amino acid substitution p.C80Y. Bioinfor-
matic analysis by SIFT (Ng  & Henikoff, 2001; Xi et  al., 
2004) and PolyPhen II (Ramensky et  al., 2002; Xi et  al., 
2004) programmes suggested that the substitution is not 
tolerated, and is predicted to be deleterious to protein 
 Table I. Variations in  SPACA3 identifi ed in all subjects. 
Nucleotide 
change
Amino acid 
change Domain
Previous 
report dbSNP ID
PolyPhen II a 
prediction
SHIFT a 
prediction
Grantham b 
score
Sequence 
conservation c 
g. – 22TGC(4_5)  – 5 ′ UTR Yes rs3052914  –  –  –  – 
c.239G  A p.C80Y Transmembrane Yes rs16967845 0.96 0.02 194 High (100% in 
 42 species)
c.691G   C  – 3 ′ UTR No  –  –  –  –  – 
 UTR, untranslated region 
 a PolyPhen II score (0 least; 1 most) and SIFT score (0 – 1;    0.05 damaging,    0.05 tolerated) predicted the damage of the variant. 
 b Grantham score classifi es the chemical dissimilarity of the variant (0 – 50 conservative, 51 – 100 moderately conservative, 101 – 150 moderately 
radical,    151 radical). 
 c Protein sequence alignment of all known orthologs ( n    42). 
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 Figure 2. Multiple sequence alignments of SPACA3 orthologs. Sequence alignments of all known SPACA3 othologs were performed in the 
programme Clustal W2 on exons one containing the g. – 22TGC(4_5) variant, exon two containing the c.239G  A variant, and exon fi ve containing 
the c.691G   C variant. Four nucleotides either side of each variant are shown. The variant region is boxed.  Dots indicate agreement with the header 
sequence (human major allele). 
structure or function. A similar prediction was observed 
using the Grantham matrix score (Abkevich et  al., 2004; 
Grantham, 1974; Lee et  al., 2008). 
 A third variant was identifi ed in exon fi ve and resulted 
in a guanosine to cytosine transversion at nucleotide 
position 691, c.691G   C (Figure 1; Table I). This novel 
SNP occurred in the 3 ′ UTR in the heterozygous form in 
one individual, an infertile female (Table II) diagnosed as 
having unexplained infertility (Supplementary Table VIII 
available online at: http//informahealthcare.com/doi/abs
/10.3109/14647273.2014.907506). The observed fre-
quencies for this variant were not signifi cantly different 
between the infertile and fertile individuals ( p    0.31). 
The TargetScanHuman programme version 6.2 (Lewis 
et  al., 2005) identifi ed that the novel variant c.691G   C 
is located in the seed region of the human miRNA 873 
(hs-miR873). 
 Discussion 
 Currently there is only limited knowledge about the 
specifi c proteins that are involved in human fertility, 
and how genetic variation in these proteins may affect 
fertility. In this study we investigated variations in the 
gene  SPACA3 which encodes SPRASA, a little studied 
protein that has a role in sperm – oocyte binding (Chiu  & 
Chamley, 2002; Chiu et  al., 2004; Herrero et  al., 2005; 
Mandal et  al., 2003) and early embryonic development 
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(A. Wagner, unpublished). Levels of population genetic 
variation in  SPACA3 were determined in a cohort of New 
Zealand males and females ( n    412). Limited variation 
was found in  SPACA3 , suggesting that this gene may 
be well conserved, possibly because its potential role in 
fertilisation (Herrero et  al., 2005; Mandal et  al., 2003) 
means that variation would be detrimental to fertility. 
 To explore whether variants in  SPACA3 are associ-
ated with infertility in the New Zealand population, 
variation was investigated in infertile and fertile couples. 
Twenty-nine variants in  SPACA3 have previously been 
recorded (NCBI SNP database http://www.ncbi.nlm.
nih.gov/). In the New Zealand population, three variants 
were found. All variants were seen at higher frequencies 
in individuals belonging to infertile, compared to fertile, 
couples. However, none of these differences were statis-
tically signifi cant. When investigating infertility, couples 
should be considered together (Campana et  al., 1995). 
Thus, analysis of couples found three variant combina-
tions in the infertile couples only, suggesting that these 
variant combinations are possibly detrimental to fertility, 
although the variant combinations were not statistically 
associated with infertility. Given that infertility has many 
causes and is often multifactorial, it may be diffi cult 
to show an association with infertility in such a broad 
collection of individuals. The variants identifi ed may 
therefore be important in the pathogenesis of infertility 
in the affected individuals. Indeed, we determined that 
the variant encoding a cysteine to a tyrosine (p.C80Y) 
transition in the putative transmembrane region may 
affect the function of SPRASA. Further, the other two 
variants may affect the expression levels of SPRASA. 
 The functional activity of Promoter A (major allele) 
in the KGN cell line was abolished when Promoter A 
g. – 22TGC(4_5) variant was transfected instead sug-
gesting that the g. – 22TGC(4_5) variant may reduce the 
expression of  SPACA3 , and could lead to an effect on 
fertility. Further, the major allele at this locus is highly 
conserved, suggesting that any variation in this region 
may be deleterious. However, the g. – 22TGC(4_5) vari-
ant was found in the homozygous state in three fertile 
couples, indicating that it does not lead to frank infertil-
ity in all individuals, and may have a subtle effect on 
fertility. A second promoter, Promoter B, is located in 
intron one. This promoter may allow the continuing 
expression of an isoform of SPRASA and, therefore, the 
continuation of some functions of SPRASA in fertility. 
 The c.239G  A variant results in a non-conservative 
change of a cysteine to tyrosine and is located in the 
putative transmembrane region of SPRASA.  In silico 
analyses suggest that this substitution is deleterious to 
the function of SPRASA, and analysis of  SPACA3 or-
thologs confi rms that the cysteine is highly conserved, 
further indicating that it may be crucial for protein 
function. The c.239G  A variant was only seen in the 
homozygous state in a single infertile female, which may 
indicate an effect on fertility of non-functional SPRASA 
in this individual. The allele frequency of the c.239G  A 
variant in the New Zealand population (0.02) is simi-
lar to the European and Asian frequencies (0.03 and 
0.01, respectively; refer to cluster reports ss227519113, 
ss23645285, and ss237222685 on dpSNP http://www.
ncbi.nlm.nih.gov/snp), indicating the potential of this 
variant to affect fertility in multiple populations. 
 The heterozygous variant c.691G   C was identi-
fi ed in a single female with unexplained infertility. 
The major variant at this locus is conserved across all 
known  SPACA3 orthologs, indicating its importance 
to the functioning of SPRASA. This variant is located 
within the seed region for hs-miR873, a miRNA 
 Table II. Allele frequencies and levels of homozygosity/heterozygosity in  SPACA3 variants identifi ed in all 
subjects. 
Nucleotide 
change
Minor allele 
frequency
Number in 
infertile  patients 
( n    204)
Frequency 
in infertile 
 patients
Number in 
fertile  controls 
( n    208)
Frequency 
in fertile 
 controls
Infertile 
patients
Fertile 
controls HO HE HO HE HO HE HO HE
g. – 22TGC(4_5) 0.137 0.098 5 46 0.025 0.226 3 35 0.014 0.168
c.239G  A 0.032 0.017 1 11 0.005 0.054 0 7 0 0.034
c.691G   C 0.002 0 0 1 0 0.005 0 0 0 0
 HO, homozygote; HE, heterozygote 
 Figure 3. Functional analysis of the human  SPACA3 gene promoter 
variants isolated in this study. Luciferase reporter assay of Promoter 
A (located fi ve-prime of exon one; major allele; 983bp), Promoter 
A g. – 22TGC(4_5) variant (located fi ve-prime of exon one; 986bp) 
and Promoter B (located in intron one; invariant) transfected into 
HEK-293T (negative control;  grey ), NCCIT ( SPACA3 -expressing 
teratocarcinoma;  blue ) and KGN ( SPACA3 -expressing granulose;  red ) 
cell lines. Data are presented as fold luciferase activity calibrated to 
the appropriate cell line transfected with the empty pGL3-enhancer. 
The  red line shows the level of the normalisation control. Results 
shown as mean    SE of three independent experiments performed in 
triplicate.  * * p    0.01. 
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(Pasten-Hidalgo et  al., 2008) that can specify post-
transcriptional repression by transcript destabilisa-
tion/translational repression (Friedman et  al., 2009). 
The identifi cation of hs-miR873 and the conservation 
of this region suggest that this locus may be important 
in the regulation of  SPACA3 by affecting the stabil-
ity and/or translation of the mRNA, thereby affecting 
levels of the SPRASA protein. 
 Summary 
 In this investigation, we have determined that  SPACA3 
has low levels of variation in our study population. 
Three variants were detected; although none were sta-
tistically associated with infertility; this is not a surpris-
ing fi nding, given the multifactorial nature of infertility. 
Furthermore, because infertility has multiple causes, 
the explanation of an individual ’ s infertility may not be 
associated with infertility when examined on a popula-
tion basis. All three of the variants were found at higher 
frequencies in the infertile cohort and one of the vari-
ants was only found in the homozygous state in an infer-
tile individual, suggesting that this could be associated 
with the pathogenesis of infertility in some individuals/
couples. Two of the variants may affect the expression 
levels of  SPACA3, and the other variant may affect the 
function of SPRASA. Results from multiple models 
indicate that SPRASA is important in fertility (Chiu 
et  al., 2004; Mandal et  al., 2003; Zhang et  al., 2005; 
A. Wagner, unpublished), and thus variants that affect 
SPRASA ’ s function or expression levels may compro-
mise fertility for some couples. Further functional stud-
ies are required to determine whether the presence of 
these variants has a role in infertility. 
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Supplementary material for Prendergast, D., et al. (2014). SPACA3 gene variants in a New Zealand cohort of infertile 
and fertile couples, Human Fertility, doi: 10.3109/14647273.2014.907506.
 Supplementary Table I. Infertility diagnosis, duration of infertility and age of the infertile couples analysed in this study. 
Classifi cation Sex/diagnosis Range (mean) Number/percentage
Age (years) Female
 Male
24 – 42 (35.0)
 26 – 52 (36.8)
n    102
 n    102
Duration of infertility (years) 1 – 14 (4)
Male factor infertility Oligospermia
 Teratospermia
 Asthenospermia
 Testicular cancer
 Vasectomy reversal
 Antisperm antibodies
n    38
 37.3%
Female factor infertility Endometriosis
 PCOS
 Raised FSH
n    17
 16.7%
Couples with both a female and male factor infertility n    18
 17.6%
Couples with unexplained infertility n    29
 28.4%
 The percentages indicate the number of male, females or couples with a diagnosed cause for their infertility. Male n    102, female n    102 and 
couples n    102. 
 Oligospermia, teratospermia and asthenospermia as defi ned by World Health Organization standards. 
 PCOS    polycystic ovary syndrome, FSH    follicle stimulating hormone. 
 Supplementary Table II. Age of the fertile couples analysed in this 
study. 
Diagnosis Range (mean)
Female
 Male
23 – 46 (35)
 23 – 51 (37)
 Male n    104, female n    104 and couples n    104. 
 Supplementary Table III. Summary of PCR primers used for mutation screening and promoter amplifi cation. 
Fragment Size Primers (5 ′ _3 ′ ) Location
Exon 1 253 bp  FOR GTGGCGCTGTTTGTGGAAGATGAG
 REV TGTTAACAGCCCCAGGAAGAAGG
 60349 – 60372 
 60556 – 60578 
Exon 2 544 bp  FOR GCCTTCTGCCCACCCCTTCTCT
 REV GGTTGCCTGCTGCCTGCCTACT
 63939 – 36960 
 64461 – 64482 
Exon 3 223 bp  FOR CTGGGGTGGCTGTAACCATCTGAC
 RE V AGGCCCAGCTACCTGAGCAGTA
 65360 – 65383 
 65561 – 65582 
Exon 4 268 bp  FOR ACAGGATTGGATTTAGGCGAGTGG
 REV ACCGCTGCGGGGCTCCAG
 65857 – 65882 
 66108 – 66125 
Exon 5 366 bp  FOR GTGGGCAGCAGCAGGGAACAAAC
 REV AACGGAGGTGCTCTGGCTCTGACA
 66141 – 66163 
 66483 – 66506 
Promoter A 983 or 986 FOR TATATAACGCGTCCAACACTACCATCCCTG
 REV ATATACTCGAGGTGACAATGGCAGCAGCA
59514 – 59531
 60479 – 60496
ProInt
 Promoter A
616 FOR CTATTCTGGGCACCAACCA
 REV ATATACTCGAGGTGACAATGGCAGCAGCA
59881 – 59898
 60479 – 60496
Promoter A
 ProInt
537 FOR TATATAACGCGTCCAACACTACCATCCCTG
 REV GGGATGTTAACAGGTGTGCAA
59514 – 59531
 60030 – 60050
Promoter BF
 Promoter BR
926 FOR GGTATAACGCGTGGTGAGGACAAGAAGCAG
 REV TATATCTCGAGATCCCAGCTGGGCACCA
63224 – 63241
 64133 – 64149
 Forward ( FOR ) and reverse ( REV ) PCR primers spanning the fi ve exons of the SPRASA gene and the promoter 
region. Size of PCR products generated by each set of primer pairs is indicated. Locations of fragments are 
indicated with reference to the reverse complements of Genbank accession number AC003687. Bases fl anking 
restrictions sites Mlu I and Xho I are highlighted in grey, the restriction sites Mlu I and Xho I are in green and 
yellow respectively and the  SPACA3 gene sequence is in black. 
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 Supplementary Table IV. Summary of PCR conditions. 
Cycle Step
Temperature  & 
Duration Function
One (1x) 94.0 ° C for 5.0 minutes Initial denaturation
Two (30x) One 94.0 ° C for 1.0 minutes Denaturation
Two 64.5 ° C for 1.0 minutes Annealing
Three 72.0 ° C for 1.0 minutes Elongation
Three (1x) 72.0 ° C for 10.0 
 minutes
Final elongation
Four (1x) 7.0 ° C for  ∞ Hold
 Supplementary Table V. Summary of Touchdown PCR conditions. 
Cycle Step
Temperature  & 
Duration Function
One (1x) 94.0 ° C for 5 minutes Initial 
denaturation
Two (20x) One 94.0 ° C for 0.45 minutes Denaturation
Two 70.0 ° C for 0.45 minutes Annealing
Decrease temperature 
after cycle one by 
0.5 ° C every 1 cycle
Annealing
Three 72.0 ° C for 1.0 minutes Elongation
Three (15x) One 94.0 ° C for 0.45 minutes Denaturation
Two 60.0 ° C for 0.45 minutes Annealing
Three 72.0 ° C for 1.0 minutes Elongation
Four (1x) 72.0 ° C for 10.0 minutes Final elongation
Five (1x) 7.0 ° C for  ∞ Hold
 Due to non-specifi c primer binding, exon two, four and the promoter 
were amplifi ed by Touchdown PCR 70 ° C – 60 ° C. 1 The promoter 
amplicons followed the same Touchdown PCR protocol as exon two 
and four with the exception that the time for the fi rst 20 cycles was 
extended to one minute. 
 1 Dieffenbach CW, Dveksler GS (eds.): PCR Primer: A Laboratory 
Manual, First Edition: Cold Spring Harbor Laboratory Press; 1995. 
 Supplementary Table VI. Summary of sequencing reaction 
conditions. 
Cycle Step
Temperature  & 
Duration Function
One (1x) 96.0 ° C for 1.0 minutes Initial 
denaturation
Two (25x) One 96.0 ° C for 0.1 minutes Denaturation
Two 50.0 ° C for 0.05 minutes Annealing
Three 60.0 ° C for 1.0 minutes Elongation
Three (1x) 15.0 ° C for  ∞ Hold
 Primers (5 μ M) used for sequencing the human SPRASA exons were 
the forward PCR primers for exons one, two, three and fi ve. Due to 
the presence of repetitive sequences in the 5 ′ end of the amplicon, the 
reverse primer for exon four was used. 
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 Supplementary Table VIII. Diagnosis of infertility in infertile patients 
with identifi ed SPACA3 variants. 
Diagnosis
g. – 22TGC(4_5) c.239G  A c.691G   C
 HO HE HO HE HO HE
Male factor 
infertility a 
0 9 0 5 0 0
Unexplained 
(male)
4 11 0 2 0 0
Endometriosis 0 4 1 2 0 0
PCOS 1 3 0 0 0 0
Unexplained 
(female)
0 19 0 2 0 1
TOTAL 5 47 b 1 11 0 1
 a Testicular cancer, oligospermia, antisperm antibodies, teratospermia 
or asthenospermia. 
 b Forty six individuals were heterozygous for g. – 22TGC(4_5), one 
female was diagnosed with both endometriosis and PCOS. 
 PCOS    polycystic ovary syndrome; HO    homozygote, HE   
heterozygote. 
 Supplementary Table VII. Variant frequencies of g. – 22TGC(4_5) and 
c.239G  A in fertile and infertile couples. 
Variant frequencies in couples
Variant combination Number
p-valuesMale Female Fertile Infertile
Wildtype Wildtype 69 56 0.43
Wildtype 5x 11 17 0.32
Wildtype A 1 2 0.64
Wildtype 5x/A 1 0 0.50
5x Wildtype 13 15 0.84
A Wildtype 1 2 0.62
5x/A Wildtype 2 0 0.25
5x 5x 4 3 1.00
5x 5x/A 1 0 0.50
5x A 0 2 0.25
5x/A 5x 0 3 0.25
A 5x 1 1 1.00
5x/A A 0 1 0.50
5x/A 5x/A 0 0  – 
A A 0 0  – 
A 5x/A 0 0  – 
 Possible combinations and the frequencies of the 5x TGC repeat (g. –
 22TGC(4_5)) and the A allele (c.239G  A) in the fertile and infertile 
couples. 
 Statistics were performed with Fisher ’ s exact t-test (2-tailed). 
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 Supplementary Table IX. The genotype analysis of the three variants identifi ed in the infertile and fertile cohorts. 
Cohort
Genotype analysis
5X allele OR 95% CI P Value 4_4 4_5 5_5
g. – 22TGC(4_5) Male Fertile Controls 84 (0.808) 18 (0.173) 2 (0.019) 22 (0.106) 0.71 0.40 – 1.29 0.55 
Infertile Cases 77 (0.755) 21 (0.206) 4 (0.039) 29 (0.142)
Female Fertile Controls 86 (0.827) 17 (0.163) 1 (0.010) 19 (0.091) 0.66 0.35 – 1.23 0.35 
Infertile Cases 76 (0.745) 25 (0.245) 1 (0.010) 27 (0.132)
Couples Fertile Controls 170 (0.817) 35 (0.168) 3 (0.014) 41 (0.099) 0.69 0.45 – 1.05 0.24 
Infertile Cases 153 (0.750) 46 (0.225) 5 (0.025) 56 (0.137)
c.239G  A GG GA AA A allele
Male Fertile Controls 100 (0962) 4 (0.038) 0 (0.000) 4 (0.019) 0.55 0.16 – 1.1 0.34 
Infertile Cases 95 (0.931) 7 (0.069) 0 (0.000) 7 (0.034)
Female Fertile Controls 101 (0.971) 3 (0.029) 0 (0.000) 3 (0.014) 0.48 0.12 – 1.96 0.55 
Infertile Cases 97 (0.951) 4 (0.039) 1 (0.010) 6 (0.029)
Couples Fertile Controls 201 (0.966) 7 (0.034) 0 (0.000) 7 (0.017) 0.52 0.21 – 1.32 0.36 
Infertile Cases 192 (0.941) 11 (0.054) 1 (0.005) 13 (0.032)
c.691G   C GG GC CC C allele
Male Fertile Controls 104 (1.000) 0 (0.000) 0 (0.000) 0 (0.000) 1.00 
Infertile Cases 102 (1.000) 0 (0.000) 0 (0.000) 0 (0.000)
Female Fertile Controls 104 (1.000) 1 (0.010) 0 (0.000) 0 (0.000) 0.31 
Infertile Cases 201 (0.990) 0 (0.000) 0 (0.000) 1 (0.005)
Couples Fertile Controls 208 (1.000) 0 (0.000) 0 (0.000) 0 (0.000) 0.31 
Infertile Cases 203 (0.995) 1 (0.005) 0 (0.000) 1 (0.002)
 OR    odds ratio; CI    confi dence interval 
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